Management of hepatic metastases

M. A. Choti, G. B. Bulkley

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Although the liver is the most common site of metastatic disease from a variety of tumor types, isolated hepatic metastases most commonly occur from colorectal cancer and, less frequently, from neuroendocrine tumors, gastrointestinal sarcoma, ocular melanoma, and others. Complete evaluation of the extent of metastatic disease, both intrahepatically and extrahepatically, is important before considering treatment options. Based on a preponderance of uncontrolled studies for hepatic metastatic colorectal carcinoma, surgical resection offers the only potential for cure of selected patients with completely resected disease, with 5-year survival rates of 25% to 46%. Systemic and hepatic arterial infusion chemotherapy may be useful treatment options in patients with unresectable disease and possibly as an adjuvant treatment after liver resection. Other techniques of local tumor ablation, including cryotherapy and radiofrequency ablation, although promising, remain unproved. Management of hepatic metastases from neuroendocrine tumors and other noncolorectal primary tumors should be individualized based on the patient's clinical course, extent of disease, and symptoms.

Original languageEnglish (US)
Pages (from-to)65-80
Number of pages16
JournalLiver Transplantation and Surgery
Volume5
Issue number1
StatePublished - 1999

Fingerprint

Neoplasm Metastasis
Liver
Neuroendocrine Tumors
Colorectal Neoplasms
Neoplasms
Cryotherapy
Sarcoma
Melanoma
Therapeutics
Survival Rate
Drug Therapy

ASJC Scopus subject areas

  • Hepatology
  • Surgery

Cite this

Management of hepatic metastases. / Choti, M. A.; Bulkley, G. B.

In: Liver Transplantation and Surgery, Vol. 5, No. 1, 1999, p. 65-80.

Research output: Contribution to journalArticle

Choti, MA & Bulkley, GB 1999, 'Management of hepatic metastases', Liver Transplantation and Surgery, vol. 5, no. 1, pp. 65-80.
Choti, M. A. ; Bulkley, G. B. / Management of hepatic metastases. In: Liver Transplantation and Surgery. 1999 ; Vol. 5, No. 1. pp. 65-80.
@article{11885d139c4e4e4a9605cb4af31d949d,
title = "Management of hepatic metastases",
abstract = "Although the liver is the most common site of metastatic disease from a variety of tumor types, isolated hepatic metastases most commonly occur from colorectal cancer and, less frequently, from neuroendocrine tumors, gastrointestinal sarcoma, ocular melanoma, and others. Complete evaluation of the extent of metastatic disease, both intrahepatically and extrahepatically, is important before considering treatment options. Based on a preponderance of uncontrolled studies for hepatic metastatic colorectal carcinoma, surgical resection offers the only potential for cure of selected patients with completely resected disease, with 5-year survival rates of 25{\%} to 46{\%}. Systemic and hepatic arterial infusion chemotherapy may be useful treatment options in patients with unresectable disease and possibly as an adjuvant treatment after liver resection. Other techniques of local tumor ablation, including cryotherapy and radiofrequency ablation, although promising, remain unproved. Management of hepatic metastases from neuroendocrine tumors and other noncolorectal primary tumors should be individualized based on the patient's clinical course, extent of disease, and symptoms.",
author = "Choti, {M. A.} and Bulkley, {G. B.}",
year = "1999",
language = "English (US)",
volume = "5",
pages = "65--80",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Management of hepatic metastases

AU - Choti, M. A.

AU - Bulkley, G. B.

PY - 1999

Y1 - 1999

N2 - Although the liver is the most common site of metastatic disease from a variety of tumor types, isolated hepatic metastases most commonly occur from colorectal cancer and, less frequently, from neuroendocrine tumors, gastrointestinal sarcoma, ocular melanoma, and others. Complete evaluation of the extent of metastatic disease, both intrahepatically and extrahepatically, is important before considering treatment options. Based on a preponderance of uncontrolled studies for hepatic metastatic colorectal carcinoma, surgical resection offers the only potential for cure of selected patients with completely resected disease, with 5-year survival rates of 25% to 46%. Systemic and hepatic arterial infusion chemotherapy may be useful treatment options in patients with unresectable disease and possibly as an adjuvant treatment after liver resection. Other techniques of local tumor ablation, including cryotherapy and radiofrequency ablation, although promising, remain unproved. Management of hepatic metastases from neuroendocrine tumors and other noncolorectal primary tumors should be individualized based on the patient's clinical course, extent of disease, and symptoms.

AB - Although the liver is the most common site of metastatic disease from a variety of tumor types, isolated hepatic metastases most commonly occur from colorectal cancer and, less frequently, from neuroendocrine tumors, gastrointestinal sarcoma, ocular melanoma, and others. Complete evaluation of the extent of metastatic disease, both intrahepatically and extrahepatically, is important before considering treatment options. Based on a preponderance of uncontrolled studies for hepatic metastatic colorectal carcinoma, surgical resection offers the only potential for cure of selected patients with completely resected disease, with 5-year survival rates of 25% to 46%. Systemic and hepatic arterial infusion chemotherapy may be useful treatment options in patients with unresectable disease and possibly as an adjuvant treatment after liver resection. Other techniques of local tumor ablation, including cryotherapy and radiofrequency ablation, although promising, remain unproved. Management of hepatic metastases from neuroendocrine tumors and other noncolorectal primary tumors should be individualized based on the patient's clinical course, extent of disease, and symptoms.

UR - http://www.scopus.com/inward/record.url?scp=0032958539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032958539&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 65

EP - 80

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 1

ER -